8-K - ZIVO Bioscience, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

ZIVO Bioscience, Inc. announced its Board of Directors has determined to voluntarily delist from OTC markets and file Form 15 to deregister with the SEC, aiming to reduce compliance costs and redirect resources to operations.

Key Takeaways

1Board determined costs of SEC reporting are no longer in best interests of stockholders, prompting deregistration decision.

2Company intends to file Form 15 on or around March 30, 2026, immediately suspending reporting obligations under the Exchange Act.

3Common stock and warrants will be voluntarily delisted from OTC markets.

4Deregistration intended to eliminate significant legal, accounting, and administrative burdens to focus on business operations.

5CEO letter anticipates meaningful AgTech revenue and potential positive cash flow in the near term as a non-reporting company.

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, and Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act o

Regulation Fd

Exhibits (3)

8-K

FORM 8-K

99.1

PRESS RELEASE

99.2

CEO LETTER TO SHAREHOLDERS